

# Different routes and forms of uterotonics for treatment of retained placenta

<b>Submission date</b> 08/05/2014	<b>Recruitment status</b> No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 03/06/2014	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 14/12/2015	<b>Condition category</b> Pregnancy and Childbirth	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

## Plain English summary of protocol

### Background and study aims

Placenta retained inside the uterus after birth is one of the major factors for excessive bleeding (haemorrhage) after childbirth. Identifying a simple way to deliver the placenta without the need for manual removal under general anaesthesia will have a positive impact for the patient and her treating doctor. Uterotonics are agents used to induce contraction of the uterus. The aim of our study is to compare the effects of three different uterotonics given by three different routes on the need for manual removal of placenta and/or the quantity of blood loss among patients with retained placenta. We also aim to find out if there are any advantages of certain routes over the others.

### Who can participate?

Women giving birth at the participating hospitals can take part in this study.

### What does the study involve?

The participants will be randomly allocated to one of three groups. Group 1 receives oxytocin through the umbilical cord vein, Group 2 receives carbetocin through the vein in the arm, and Group 3 receives misoprostol placed under the tongue.

### What are the possible benefits and risks of participating?

The medication given can help the delivery of the placenta so that manual removal under general anaesthesia can be avoided. No risks are expected for participants.

### Where is the study run from?

The study is run from Menoufiya University Hospitals in Egypt and Al-Hayat National Hospital in Saudi Arabia.

### When is the study starting and how long is it expected to run for?

June 2014 to January 2016.

### Who is funding the study?

Menoufiya University Hospital (Egypt) and Al-Hayat National Hospital (Saudi Arabia).

Who is the main contact?  
Dr Mohammad Maher  
mohamaher2015@gmail.com

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr Mohammad Maher

**ORCID ID**  
<http://orcid.org/0000-0002-7332-5215>

**Contact details**  
Al-Hayat National Hospital  
Umm Sarar  
Khamis Mushyat  
Saudi Arabia  
101

## Additional identifiers

**EudraCT/CTIS number**

**IRAS number**

**ClinicalTrials.gov number**

**Secondary identifying numbers**  
1

## Study information

**Scientific Title**  
Different routes and forms of uterotonics for treatment of retained placenta: a randomized clinical trial

**Study objectives**  
The aim of our study is to compare three different forms of uterotonics (oxytocin, carbetocin and misoprostol) given by three different routes (intra-umbilical, intravenous and sublingual, respectively) on the incidence of manual removal of placenta (MROP) and/or the quantity of blood loss among patients with retained placenta (RP) and also to exploit the advantage of a certain route over the others if any.

**Ethics approval required**  
Old ethics approval format

**Ethics approval(s)**

The Ethics Committee of the Obstetrics and Gynecology Departments in two collaborative centers (Menoufiya University Hospitals in Egypt and Al-Hayat National Hospital in Saudi Arabia), 06/05/2014

## **Study design**

Prospective randomized non-blind non-placebo-controlled trial

## **Primary study design**

Interventional

## **Secondary study design**

Randomized non-blind non-placebo-controlled trial

## **Study setting(s)**

Hospital

## **Study type(s)**

Treatment

## **Participant information sheet**

Not available in web format, please use the contact details below to request a patient information sheet

## **Health condition(s) or problem(s) studied**

Retained placenta

## **Interventions**

The enrolled participants will be allocated randomly into three groups. The trial allocation sequence for all cases enrolled will be developed using a computer-generated random number table. Sequentially numbered sealed opaque envelopes will be used to hide the generated allocation sequence. Each envelope contains a single assignation to either Group A, Group B or Group C. Women are allocated to one of the following three regimens by opening one of the sequentially numbered sealed opaque envelopes.

Group A women will receive oxytocin (Syntocinon®, Novartis Pharma AG, Basel, Switzerland) via fetal cord umbilical vein. The umbilical cord is re-cut to achieve a clean end through which a nasogastric tube is passed into the umbilical vein until resistance is felt then withdrawing 5 cm of it to allow for any divisions of the vein prior to its insertion in the placenta. 30 IU oxytocin is diluted in 20 ml of normal saline and injected directly down the nasogastric tube in the umbilical vein. After the injection of the solution, the cord is clamped with the catheter in position for 10 minutes prior to trying controlled cord traction.

Group B women will receive Carbetocin (Pabal®, Ferring GmbH, Kiel, Germany). One ampoule is diluted in 10 ml normal saline and administered slowly intravenously over 30-60 seconds.

Group C women will receive sublingually 400 ug of misoprostol (Cytotec®, GD SEARLE LLC, USA). The envelopes will be prepared by the medical research officer in both hospitals and all authors will be unaware of the envelopes' contents.

## **Intervention Type**

Drug

**Phase**

Not Applicable

**Drug/device/biological/vaccine name(s)**

Oxytocin, carbetocin, misoprostol

**Primary outcome measure**

1. Delivery of the placenta within 30 minutes following drug administration (either spontaneously or following controlled cord traction)
2. The need for MROP

**Secondary outcome measures**

1. Post-partum hemorrhage defined as drop in the hemoglobin of 2 g/dl between the pre-randomization level or that taken at least 2 weeks before delivery and the hemoglobin measured 24 hours after delivery
2. Need for blood transfusion at any time before discharge from the hospital
3. Need for additional uterotonic agents to control post-partum hemorrhage
4. Need for uterine curettage

**Overall study start date**

01/06/2014

**Completion date**

31/01/2016

**Eligibility****Key inclusion criteria**

1. Booked or un-booked patients who deliver in the study hospitals or those who are transferred to them after delivering elsewhere
2. Gestational age of 28 weeks or more (updated 11/08/2015: was previously 20 weeks or more)
3. Singleton pregnancies
4.  $\geq 30$  minutes interval after the delivery of the baby provided that our routine active management of the third stage was implemented

**Participant type(s)**

Patient

**Age group**

Adult

**Sex**

Female

**Target number of participants**

281

**Key exclusion criteria**

1. Maternal hemodynamic instability requiring immediate intervention (pulse > 100 beats per minute, systolic blood pressure <100 mmHg, diastolic blood pressure reduction more than 20 mmHg)
2. Severe postpartum hemorrhage requiring immediate intervention
3. History of RP or MROP in any previous delivery
4. Vaginal birth after previous cesarean scar
5. Associated medical disorders (e.g., pre-eclampsia, gestational hypertension, pre-gestational and gestational diabetes, cardiac diseases)
6. Placenta previa in the current pregnancy or previous pregnancies
7. Stillborn baby
8. Snapped umbilical cord
9. Known uterine anomalies

**Date of first enrolment**

08/06/2014

**Date of final enrolment**

31/12/2015

## Locations

**Countries of recruitment**

Egypt

Saudi Arabia

**Study participating centre**

**Al-Hayat National Hospital**

Khamis Mushyat

Saudi Arabia

101

**Study participating centre**

**Menoufiya University Hospital**

Shebin Elkom

Egypt

101

## Sponsor information

**Organisation**

Al-Hayat National Hospital (Saudi Arabia)

**Sponsor details**

Umm Sarar  
Khamis Mushyat  
Saudi Arabia  
101

**Sponsor type**

Hospital/treatment centre

**Organisation**

Menoufiya University Hospital (Egypt)

**Sponsor details**

-

Shebin Elkom  
Egypt

-

**Sponsor type**

Hospital/treatment centre

**Funder(s)****Funder type**

Hospital/treatment centre

**Funder Name**

Menoufiya University Hospital (Egypt)

**Funder Name**

Al-Hayat National Hospital (Saudi Arabia)

**Results and Publications****Publication and dissemination plan**

To be confirmed at a later date

**Intention to publish date****Individual participant data (IPD) sharing plan**

## **IPD sharing plan summary**

Not provided at time of registration